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Abstract 
Non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of the 
anaplastic lymphoma kinase (ALK) gene is treated with ALK tyrosine kinase inhibitors 
(TKIs), but is successful for only a limited amount of time; most cases relapse due to the 
development of drug resistance. Here we show that a vaccine against ALK induced a 
strong and specific immune response that both prophylactically and therapeutically 
impaired the growth of ALK-positive lung tumors in mouse models. The ALK vaccine was 
efficacious also in combination with ALK TKI treatment and significantly delayed tumor 
relapses after TKI suspension. We found that lung tumors containing ALK rearrangements 
induced an immunosuppressive microenvironment, regulating the expression of PD-L1 on 
the surface of lung tumor cells. High PD-L1 expression reduced ALK vaccine efficacy, 
which could be restored by administration of anti-PD-1 immunotherapy. Thus, 
combinations of ALK vaccine with TKIs and immune checkpoint blockade therapies might 
represent a powerful strategy for the treatment of ALK-driven NSCLC. 
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Introduction 
Lung cancer is the leading cause of cancer-related mortality worldwide. In recent years, 
the identification of key genetic alterations in non-small-cell lung cancer (NSCLC) has 
prompted the use of rationally targeted therapies, which showed unprecedented clinical 
benefits (1,2). Approximately 5-6% of NSCLC have chromosomal rearrangements of the 
anaplastic lymphoma kinase (ALK) gene that generate different chimeric proteins, such as 
EML4-ALK, TFG-ALK, and KIF5b-ALK (3-5). In all such fusions, constitutively active ALK 
acts as a potent tumorigenic driver that activates downstream oncogenic signals, leading 
to increased cell proliferation and survival (4).  
Experimental and clinical data show that ALK-rearranged NSCLCs respond to treatment 
with specific tyrosine kinase inhibitors (TKIs), such as crizotinib (6,7). Despite a high rate 
of initial response, the development of resistance to crizotinib almost invariably leads to 
tumor relapse and eventually to the patient’s death (8,9). Next-generation ALK TKIs, such 
as ceritinib and alectinib, have been developed to overcome crizotinib resistance and can 
further extend survival in crizotinib-resistant patients (10-12). Resistance to ALK TKIs is 
mediated by point mutations of the ALK kinase domain, by ALK gene amplification, or by 
activation of other compensatory pathways, so-called bypass tracks, such as EGFR, c-KIT, 
c-MET, and IGF-R1 (8,13-16). Thus, additional therapies to be combined with ALK TKIs 
are needed to further prolong remission or clinical response in NSCLC patients with ALK 
rearrangements.  
Immunotherapy aimed at enhancing the immune response against tumor cells shows 
promising efficacy in a fraction of NSCLC (17,18). In this context, the ALK protein has 
many features of an ideal tumor oncoantigen that can be exploited to design specific 
immunotherapies, such as a cancer vaccine. ALK is required for tumor survival and growth 
and expressed minimally in some nervous system cells (4,19). ALK is also antigenic in 
humans, as lymphoma patients with ALK rearrangements mount spontaneous B- and T-
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cell responses against the ALK protein, with measurable antibodies (20), cytotoxic T 
lymphocytes (CTLs), and CD4+ T helper effectors to ALK epitopes (21-24). A robust 
immune response to ALK is associated with a decreased risk of relapse in lymphoma 
patients (25). Our previous ALK vaccine in pre-clinical mouse models of lymphoma 
containing ALK rearrangements induced specific and potent immune responses that 
provided strong and durable tumor protection (19).  
We here test the efficacy of ALK vaccination in lung cancer. Grafted or primary mouse 
models of ALK-positive lung tumors demonstrated that an ALK vaccine elicited a strong, 
ALK-specific CTL response in both mouse models, efficiently blocking tumor growth.  
 
Materials and Methods 
 
Cell Lines and Reagents.  
Human ALK-rearranged NSCLC cell lines, H2228 (variant 3, E6;A20), DFCI032 and 
H3122 (variant 1, E13;A20) were obtained from the ATCC collection and were passaged 
for fewer than 6 months after receipt and resuscitation. These cell lines were further 
internally tested for the presence of EML-ALK rearrangement. The murine ASB-XIV cell 
line was purchased from Cell Lines Service (CLS) and was passaged for fewer than 6 
months after receipt and resuscitation.  
ALK TKIs, NVP-TAE684 was purchased from Axon Medchem and crizotinib (PF-
02341066) was kindly gifted by Pfizer.  
 
Mice. Strains of mice used in this study include K-RasLSL/G12V and Tg EGFRL858R, as 
previously published (26,27), and BALB/c mice (Charles River). Mice were handled and 
treated in accordance with European Community guidelines. 
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Generation of ALK Transgenic Mice. A cDNA fragment encoding EML4-ALK (variant 1, 
E13;A20) or TFG-ALK was ligated to the human SP-C promoter as well as to a 
polyadenylation signals (Supplementary Figure 1A). The expression cassette was injected 
into pronuclear-stage embryos of FVB/N mice. The presence of the transgene was 
examined by PCR analysis with DNA from the tail of founder animals. Mice were handled 
and treated in accordance with European Community guidelines. Methods are further 
described in Supplementary Materials and Methods.  
 
DNA Vaccination and In Vivo Cytotoxicity Assay. For DNA vaccination, 50 µg of 
pDEST or pDEST-ALK plasmids were used as previously described (19). The In Vivo 
Cytotoxicity Assay was previously reported(19). 
 
Antibody dosing for in vivo treatment 
For CD4+ and CD8+ cell depletion, anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) 
antibodies were purchased from BioXcell. For depletion mice were injected i.p. with 100µg 
of anti-CD4 or anti-CD8 at day -1, +5, +15 and +25.  
For PD-1 blockade, anti-PD-1 (clone J43) and control anti-hamster polyclonal IgG for the 
in vivo experiments were purchased from BioXcell. Mice received 200µg of each anti-PD-1 
and anti-PD-L1 or 200µg of anti-hamster IgG i.p. every 3 days for a total of 5 injections.  
 
Magnetic Resonance Imaging. MR images were acquired on a Bruker Avance 300 
spectrometer operating at 7 T and equipped with a microimaging probe (Bruker Bio-Spin), 
as described in the Supplementary Materials and Methods.  
 
Histology and Immunohistochemistry. For histological evaluation, tissue samples were 
fixed in formalin, embedded in paraffin, stained and visualized as previously described(19). 
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T lymphocytes and Treg cells were quantified by measuring the number of CD3+, CD8+, 
CD4+ and Foxp3+ cells, respectively, among the total tumor cells. 
 
Intratumoral Cell Characterization. For flow cytometry analysis, lung cell infiltrate was 
obtained using the Lung Dissociation Kit (Miltenyi Biotec) following manufacturer’s 
instructions. Cells were resuspended in phosphate buffer and stained with antibodies 
described in Supplementary Materials and Methods. 
 
Statistical Methods. Kaplan-Meier analyses for survival curves were performed with 
GraphPad Prism 5 and p values were determined with a log-rank Mantel-Cox test. Paired 
data were compared with the Student’s t test. P values of <0.05 were considered to be 
significant. Unless otherwise noted, data are presented as means ± SEM.  
 
 
Results 
 
ALK vaccination elicits a specific cytotoxic response and prevents tumor growth in 
an orthotopic model of ALK-positive lung cancer.  
To test the efficacy of the ALK vaccine against lung cancer, we developed an orthotopic 
mouse model of ALK-positive lung cancer by ectopic expression of EML4-ALK in the 
syngeneic BALB/c murine lung cancer cell line ASB-XIV. We transduced ASB-XIV cells 
with a retroviral vector containing the EML4-ALK cDNA (variant 1) and green fluorescent 
protein (GFP) as a reporter. Protein expression in transduced ASB-XIV cells was 
comparable to EML4-ALK expression in human ALK-rearranged NSCLC cells (variant 1 in 
H3122 and 3 in H2228) (Fig. 1A). ASB-XIV cells express MHC class I and thus are 
suitable for tumor immune studies (Fig. 1B). Within 3 weeks after i.v. injection of 5 x 105 
ASB-XIV cells into the mouse tail vein, tumor nodules were detected in both lungs (Fig. 1, 
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E and F). We vaccinated BALB/c mice with a DNA plasmid coding for the intracytoplasmic 
domain of ALK (19) (Fig. 1C).  
ALK vaccine induced a strong ALK-specific immune response as measured by an in vivo 
cytotoxic assay (19) (Fig. 1D). Ten days after the second vaccination, we injected EML4-
ALK or GFP ASB-XIV cells. GFP ASB-XIV cells gave equal numbers of tumors in mice 
vaccinated with either a control or the ALK plasmid (Fig. 1E). In contrast, tumors of EML4-
ALK ASB-XIV cells had impaired growth in ALK vaccinated mice (Fig. 1F). Thus, ALK 
vaccination induced an ALK-specific immune response that efficiently prevented the 
growth of ALK-positive lung tumors.  
 
ALK vaccination delays tumor growth and increases the overall survival of EML4-
ALK-rearranged NSCLC Tg mice.  
To test the efficacy of the ALK vaccine as a therapy for primary lung tumors, we generated 
two transgenic (Tg) mouse models of ALK-driven lung cancers. Two rearrangements of 
ALK (EML4-ALK, variant 1, or TFG-ALK) were expressed under the human lung-specific 
surfactant protein-C (SP-C) promoter (Supplementary Fig. S1A), because human ALK-
rearranged NSCLC are often SP-C positive (28), and the expression of EML4-ALK by the 
SP-C promoter can induce efficient lung tumor formation in mice (29). Both transgenic 
mouse models expressed the ALK fusion selectively in lung epithelial cells, in amounts 
comparable to human NSCLC with rearranged ALK (Supplementary Fig. S1. B-D) and 
rapidly developed multifocal ALK+ tumors few weeks after birth, with 100% penetrance 
(Supplementary Fig. 1, E and F). Tumors were mainly well-differentiated adenocarcinoma 
growing as papillary, acinar, or more solid carcinoma (30). Ki-67 immunostaining showed 
that these tumors had a proliferation rate of 10.5% ±1.4 for EML4-ALK and 8.5% ±1.9 for 
TFG-ALK (Supplementary Fig. S1G). At 4 weeks of age, a few tumor nodules in both ALK 
mice (Supplementary Fig. S1, H and I, left panels) were detected by magnetic resonance 
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imaging (MRI). Existing nodules rapidly expanded in volume and new nodules appeared in 
the lungs over time (Supplementary Fig. S1, H and I, central and right panels). No tumor 
metastases were detected by examination of other organs with MRI or histology in ALK 
mice at any age, consistent with other constitutive or ALK-inducible mice (29,31). Both 
EML4-ALK and TFG-ALK mice died within 50 weeks, with a mean survival of 33.25 weeks 
for EML4-ALK mice and 37 weeks for TFG-ALK mice (Supplementary Fig. S1L).  
To test the efficacy of the ALK vaccine, we screened ALK mice by MRI to stratify them 
according to their tumor burden. ALK mice were vaccinated at 4 weeks of age, when 
tumors were detectable in the lungs (Supplementary Fig. S1, H and I), according to the 
protocol in Fig. 2A. The ALK vaccine generated strong ALK-specific cytotoxic activity in 
both ALK models, comparable to WT littermates (Fig. 2B). In EML4-ALK mice, the average 
number of tumors detected in control mice was 58±6.0 by week 20, whereas ALK 
vaccinated mice had only 16±3.5 at the same time point (Fig. 2, C and D). Similar results 
were observed in TFG-ALK mice at 20 weeks of age (67±6.0 nodules in control mice 
compared to 20 ±3.5 nodules in vaccinated mice; Fig. 2E and Supplementary Fig. S2A). 
Correspondingly, the overall tumor burden calculated in terms of tumor volumes by serial 
MRI was significantly lower in ALK vaccinated than in control mice (Supplementary Fig. S2, 
B and C). Survival of ALK vaccinated mice was significantly extended by at least 18 weeks 
in EML4-ALK and by 12 weeks in TFG-ALK mice (Fig. 2, F and G). The ALK vaccine was 
still efficacious against larger tumors in older mice (Supplementary Fig. S2D). Thus, ALK-
DNA vaccination was a potent controller of growth of primary ALK-rearranged lung tumors. 
 
ALK-DNA vaccination increases the number of intratumoral T cells and requires 
CD8+ T lymphocytes. 
Next, we examined how the ALK vaccine shaped the intratumoral immune infiltrate. The 
ALK vaccine increased the number of intratumoral T cells in both EML4-ALK and TFG-
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ALK mice, which was associated with a reduced tumor size (Fig. 3, A and B). Both CD4+ 
and CD8+ T cells were significantly increased in ALK vaccinated mice (Fig. 3C). In ALK 
vaccinated mice tumor-infiltrating T cells had a significantly higher CD8+/CD4+ ratio 
compared to controls, due to the DNA vaccine preferentially stimulating a CD8+ T cell 
immune response (Fig. 3C) (32). We also observed an increase in intratumoral Treg cells 
(Fig. 3, D and E), suggesting that the ALK vaccine induces both Teff and Treg cells, as 
described for other tumor vaccines (33). Nonetheless, the ratio CD8+/Foxp3+ was higher in 
vaccinated mice than in control mice (Fig. 3E).  
To confirm that the ALK vaccine required Teff for its anti-tumor functions, we used repeated 
injections of antibodies specific for CD4+ and CD8+ T cells to deplete them in the orthotopic 
model based on EML4-ALK ASB-XIV cells (Fig. 3F). The depletion of CD8+ T cells, but not 
CD4+ T cells, significantly reduced the ALK vaccine efficacy (Fig. 3, G and H). Therefore, 
in mice bearing ALK-positive tumors, ALK vaccination elicited a cytotoxic response largely 
mediated by CD8+ T cells. However, in mice depleted of CD8+ T cells the vaccine still 
appeared to retain some activity, suggesting that other factors may be involved in the 
immune response elicited by the vaccine. 
 
Immunosuppressive lung microenvironment in ALK-rearranged lung cancer. 
We showed that the ALK vaccine stimulates a potent immune response against ALK-
rearranged lung tumors. However, the ALK vaccine did not cure the mice, which died after 
a delay in tumor growth (Fig. 2). Because ALK was still expressed in late tumors, we 
asked whether the efficacy of the ALK vaccine would diminish over time due to an 
immunosuppressive microenvironment that progressively develops in lung tumors with 
ALK rearrangements. Indeed, oncogenic activation of EGFR in lung cancers induces an 
immunosuppressive lung microenvironment by induction of PD-L1 expression on the 
surface of tumor lung epithelial cells (34).  
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First, we better characterized the immune infiltrate in mice bearing ALK lung tumors and 
observed that overall the percentage of B and T lymphocytes, natural killer (NK) cells and 
granulocytes were comparable between WT and EML4-ALK mice (Supplementary Fig. S3, 
A-D). However, T cells in tumor bearing EML4-ALK mice displayed a significantly higher 
expression of PD-1 on both CD4+ and CD8+ T cells (Fig. 4A and Supplementary Fig. S3E) 
and PD-1+CD3+ T cells also expressed other T cell inhibitory molecules such as LAG-3 
and TIM-3 in higher amounts (Supplementary Fig. S3E). In addition, Foxp3+ Treg cells were 
also increased in EML4-ALK mice over time (Supplementary Fig. S3F). These data 
suggest that tumor lungs bearing EML4-ALK develop an immunosuppressive 
microenvironment reminiscent of that seen in EGFR-driven lung cancer models (34).  
We also characterized the immune microenvironment in human ALK-rearranged NSCLC. 
NSCLC patients with ALK rearrangements had lower percentages of CD3+, CD4+, and 
CD8+ intratumoral T-cell infiltrate than EGFR-mutated NSCLC (Fig. 4B). These findings 
were further extended by interrogating gene-expression profiling data from larger series of 
human NSCLC with different oncogenic mutations. By gene set enrichment analysis, we 
found lower expression of tumor-infiltrating T-cell related molecules in EML4-ALK NSCLC 
compared to EGFR-mutated, K-RAS-mutated or ALK/RAS/EGFR non-mutated NSCLC 
(Fig. 4C). In particular, in ALK-rearranged tumors we observed significant depletion of 
TCR-related molecules such as TCRβ chain, CD3δ, CD3γ, CD3ζ, Lck, of the T cell 
costimulatory molecules ICOS and CD28, as well as of CD80 and CTLA-4 (Supplementary 
Fig. S4, A-D).  
 
Blockade of PD-1/PD-L1 pathway restores ALK vaccine efficacy against tumor cells 
with high levels of PD-L1. 
We asked whether oncogenic ALK could also regulate PD-L1 expression on lung tumors. 
Tumors derived from EML4-ALK mice had higher levels of PD-L1 expression than tumors 
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originating in mice carrying other NSCLC recurrent mutations, such as the K-RasG12V (26) 
and EGFRL858R (27) mice (Supplementary Fig. S5A). Next, we analyzed PD-L1 expression 
by flow cytometry and showed that tumor epithelial cells (CD45-/EpCAM+) and associated 
hematopoietic cells (CD45+) in EML4-ALK mice expressed PD-L1 (Supplementary Fig. 
S5B). To determine whether ALK oncogenic activity directly controlled PD-L1 expression 
in NSCLC, we treated three ALK-rearranged NSCLC cell lines (H3122, H2228 and 
DFCI032) with crizotinib to inhibit ALK activity (Fig. 5A and Supplementary Fig. S5C). 
Expression of PD-L1 was detectable in all ALK-rearranged cell lines tested and was 
reduced upon ALK inhibition in all three cell lines (Fig. 5B and Supplementary Fig. S5D). 
Consistently, also PD-L1 mRNA was down-regulated (Fig. 5C and Supplementary Fig. 
S5E). To further confirm that PD-L1 expression was driven by ALK activity, and to exclude 
that PD-L1 down-regulation was mediated by crizotinib inhibition of MET, ROS1, or other 
off-targets, we knocked down EML4-ALK by a doxycycline inducible shRNA system (16). 
Again, PD-L1 expression was down-regulated upon EML4-ALK knock-down 
(Supplementary Fig. S5, F and G). We conclude that in ALK-rearranged NSCLC, PD-L1 
mRNA and protein was regulated by ALK activity. Another group has recently confirmed 
these findings (35).  
The expression of PD-L1 of the surface of tumor cells impairs anti-tumor activity of the 
immune system (36). We investigated whether the efficacy of the ALK vaccine could be 
diminished by the expression of PD-L1 on the surface of the target lung tumor cells. 
EML4-ALK mice express moderate, but detectable PD-L1, and we observed similar 
intensity of expression by flow cytometry in EML4-ALK ASB-XIV (Fig. 5D). We reasoned 
that ALK vaccine efficacy could be hampered when target tumor cells express more PD-L1. 
We engineered EML4-ALK ASB-XIV cells to express more PD-L1 than parental cells by 
transduction with a lentivirus containing a murine PD-L1 construct (Fig. 5D). Vaccinated 
mice were injected with control EML4-ALK ASB-XIV cells or EML4-ALK ASB-XIV cells 
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expressing high PD-L1. In presence of high PD-L1 expression, the ALK vaccine was less 
effective in preventing lung tumor growth (Fig. 5E), suggesting that the function of ALK-
specific Teff cells was modulated by the amount of PD-L1 on the surface of target lung 
tumor cells.  
To test whether administration of antibody to PD-1 could restore a full efficacy of the ALK 
vaccine, we treated mice with anti-PD-1 or control IgG (Supplementary Fig. S6A). The 
treatment with anti-PD-1 alone, as well as control IgG, did not have significant effect on 
tumor growth and mice developed tumors comparable to controls. In contrast, anti-PD-1 
treatment almost completely restored the efficacy of the ALK vaccine (Fig. 5F). These 
results are consistent with findings that immune checkpoint therapy restores an adaptive 
immune response best in patients with high PD-L1 expression (37,38). 
To show that blockade of the PD-L1/PD-1 immune checkpoint was effective with 
physiological expression of PD-L1, we tested anti-PD-1 treatment in EML4-ALK mice 
(Supplementary Figure S6B). We observed a stabilization of tumors immediately at the 
end of treatment (Fig. 5G) followed by a slower growth rate as compared to control mice 
(Fig. 5H). These data suggest that immune checkpoint blockade therapy could be 
efficacious in the physiological tumor microenvironment of ALK-rearranged lung tumors.  
 
ALK vaccination is effective in combination with ALK TKIs.  
Crizotinib treatment of NSCLC patients with ALK rearrangements has had success in 
clinical trials, supporting the use of ALK TKIs as main therapy for NSCLC (39). A 
combination of ALK TKIs with the ALK vaccine could be an attractive therapeutic 
possibility for NSCLC patients. In this context, ALK TKIs could reduce the tumor burden to 
facilitate the activity of the ALK vaccine. We tested this combination in our ALK mouse 
models. ALK mice were treated with crizotinib (PF-02341066) for 2 weeks (100mg/kg) and 
concurrently vaccinated with the ALK or control vaccine (Fig. 6A). The immune response 
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elicited by the vaccine was not affected by administration of crizotinib, as an equally strong 
ALK-specific cytotoxic immune response in vivo was also detected in ALK-vaccinated mice 
treated with crizotinib (Fig. 6B). As expected, treatment with crizotinib induced the 
regression of tumors in both groups within 2 weeks (Fig. 6C, left and central panels, and 
6D). At 6 weeks from treatment suspension, tumors relapsed at the same sites in crizotinib 
treated mice (Fig. 6C, top right panels), while the combination of crizotinib and ALK 
vaccine delayed tumor recurrence (Fig. 6C, bottom right panels). Indeed, mice treated with 
crizotinib showed relapses and new tumors at 10 weeks from treatment suspension, 
whereas in ALK-vaccinated mice relapses and new tumors were less numerous and 
significantly smaller (Fig. 6, D and E).  Similar results were obtained when EML4-ALK 
mice were vaccinated during treatment with TAE684 (25mg/kg) (Supplementary Fig. S7, 
A-C). Thus, the ALK vaccine might be efficiently combined with ALK TKI treatment to 
delay tumor relapse after crizotinib suspension. 
 
ALK vaccination prevents growth of tumors expressing crizotinib-resistant ALK 
mutations.  
Human NSCLC patients treated with ALK TKI almost invariably develop resistance. 
L1196M, C1156Y, and F1174L are common ALK mutations found in patients relapsing 
under treatment with crizotinib (8,13,40). Point mutations in the ALK kinase domain have 
the potential to alter the antigenicity of ALK as they can modify its protein structure. To test 
the activity of the ALK vaccine against these mutants, we transduced ASB-XIV cells with a 
retroviral vector containing either the EML4-ALK wild-type (41) or the EML4-ALK mutants 
(Fig. 7A). Control mice injected with ASB-XIV cells expressing the L1196M, C1156Y or 
F1174L EML4-ALK mutants rapidly developed tumors in the lungs, whereas ALK 
vaccination almost completely prevented tumor growth of EML4-ALK WT and all mutants 
(Figures 7B-E). Therefore, the ALK vaccine is not only efficacious against the EML4-ALK 
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WT but also against some of the most common EML4-ALK mutants that develop in 
patients during treatment with crizotinib or ceritinib. 
 
Discussion 
In this work we extended our previous findings on the efficacy of a DNA ALK vaccine 
against ALK-positive lymphoma to ALK-rearranged lung cancers. Compared to our 
previous work, we showed that the ALK vaccine is active not only in tumor grafts but also 
in primary ALK-rearranged NSCLC. Because the SP-C promoter is active since embryonic 
development (42), these mice are likely tolerant to human ALK. Thus, an important 
advance from this work is the demonstration that an ALK vaccine can overcome tolerance 
in mice.  
In addition, we showed that the ALK vaccine could be combined with either ALK TKI 
treatment or the anti-PD-1 antibody. These combinatorial therapies make the ALK vaccine 
attractive for potential clinical use. Current therapies for ALK-rearranged NSCLC, based 
on crizotinib or next-generation ALK TKIs, achieve a clinical response by arresting tumor 
progression or inducing tumor regression. However, all patients eventually relapse and die 
due to development of TKI resistance (11,43). 
In this work, we set the stage for the application of an ALK vaccine to further extend 
progression-free survival in NSCLC patients. The ALK vaccine induced a strong systemic 
and intratumoral immune response in mouse models of ALK-rearranged NSCLC, 
significantly reducing tumor growth and extending survival of treated mice, regardless of 
the type of ALK translocation (EML4-ALK or TFG-ALK). Simultaneous treatment during 
vaccination with crizotinib or TAE684 did not affect the ALK immune response achieved by 
the vaccine. Thus, these data indicate the feasibility of administering an ALK vaccine to 
NSCLC patients during ALK TKI treatment, possibly when the response is maximal in 
terms of tumor burden reduction.  
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Additional advantages of such combination could stem by the potential activity of ALK 
TKIs in the regulation of the tumor immune microenvironment. We showed that the 
oncogenic activity of ALK directly regulated PD-L1 expression of the surface of tumor cells. 
High PD-L1 expression impaired the immune response against ALK elicited by the vaccine 
(Fig. 5). Therefore, PD-L1 down-regulation by ALK TKI treatment could relieve the 
inhibitory feed-back on intratumoral T cells and facilitate ALK-specific immune responses. 
Tumor cell death induced by ALK TKIs could release additional tumor neoantigens, 
including ALK itself, and thus enhance antitumor immune response  (44,45). Further 
investigation to elucidate the effect of ALK TKIs on the tumor microenvironment is required, 
but it is intriguing that studies in mouse models and metastatic melanoma patients showed 
an enhanced anti-tumor immune response after treatment with the selective B-RAF 
inhibitor (vemurafenib) alone, or in combination with MEK inhibitors (41,46).  
The immune microenvironment in ALK-rearranged tumors could be, therefore, a critical 
factor to the ALK-specific immune responses. We presented data indicating that ALK-
rearranged mice indeed progressively develop an immunosuppressive tumor 
microenvironment similar to that induced in mice by oncogenic EGFR (34). Compared to 
WT mice, ALK-rearranged lungs accumulated higher numbers of PD-1+ T cells that also 
expressed the exhaustion markers TIM-3 and LAG-3, and showed increased numbers of 
tumor infiltrating Treg cells. ALK-rearranged NSCLC patients also showed a likely 
immunosuppressive microenvironment in the lungs with reduced tumor infiltrating T cells. 
In ALK-vaccinated lungs, the tumor infiltrating Treg cells were increased and we detected a 
population of intratumoral CD8+ T cell with high expression of PD-1 (Supplementary Fig. 
S8, A and B), that we interpreted as exhausted CD8+ T cells, that had been elicited by the 
ALK vaccine to recognize the ALK antigen (47). In mice with advanced tumors, the ALK 
vaccine elicited a weaker ALK-specific cytotoxic response (Supplementary Fig. S8C) and 
decreased anti-tumor activity (Supplementary Fig.S2D). In these settings, Treg depletion by 
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an antibody to CD25 could partially restore the impaired cytotoxic activity generated by the 
ALK vaccine (Supplementary Fig. S8C), indicating that Treg cells could also play a critical 
role in the immunosuppressive tumor environment seen in ALK-rearranged lung tumors. 
Similarly, the restoration of the ALK vaccine efficacy by administration of antibody to PD-1 
in high-PD-L1 EML4-ALK ASB-XIV xenografts (Fig. 5) suggests that blockade of immune 
checkpoint molecules could powerfully potentiate the ALK vaccine. 
Overall, these data suggest that combination therapy of ALK TKIs and ALK vaccine could 
work efficiently in the clinical setting to generate a strong and long-lasting immune 
response to ALK in NSCLC. The benefit from combined ALK TKI and ALK vaccine therapy 
can be enhanced by additional immunotherapies, such as anti-PD-1/PD-L1 and anti-CTLA 
to block immune checkpoints (17,18) or through Treg depletion by antibodies to CD25 (48). 
Thus, the development of an ALK vaccine for clinical use together with additional 
immunotherapeutic tools provides exciting therapeutic options for the treatment of ALK-
rearranged NSCLC. 
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Figure Legends 
 
Figure 1. Prophylactic ALK vaccine prevents the growth of ALK-positive lung 
tumors in an orthotopic model.  A, EML4-ALK expression in ASB-XIV infected cells and 
in human EML4-ALK NSCLC cell lines (H3122 and H2228) was evaluated by 
immunoblotting with the indicated antibodies. B, Analysis of the Major Histocompatibility 
Complex (MHC) Class I (PE-H2Dd Ab) antigen expression on ASB-XIV cells by flow 
cytometry. C, Schematic representation of ALK vaccination protocol in BALB/c mice. 
Control mice were vaccinated with empty pDEST (Ctrl) and ALK vaccinated mice were 
vaccinated with pDEST-ALK (Vax). D, Cytotoxic activity in ALK vaccinated mice evaluated 
by an in vivo cytotoxicity assay. Horizontal bars represent means. E and F, Representative 
hematoxilin-eosin (H&E) sections of lungs injected with GFP-ASB-XIV cells (E) or EML4-
ALK ASB-XIV cells (F). Histograms represent the number of tumors in control (Ctrl; n=3 
mice) and ALK vaccinated mice (Vax; n=3 mice). Scale bars, 1mm (top) and 50µm 
(bottom). The total number of tumors was counted in the whole lung of each mouse. Data 
are represented from three independent experiments as mean (±SEM). ***, P<0.0001. 
 
Figure 2. Therapeutic ALK vaccine delays tumor progression in ALK-rearranged 
NSCLC. 
A, ALK vaccination protocol in ALK Tg mice. MRI, Magnetic Resonance Imaging. B, 
Cytotoxic activity in control mice (○) and ALK vaccinated (Vax) WT mice (□) or Tg mice 
(■). Horizontal bars represent means. C, Representative coronal MRI sections of lungs 
from EML4-ALK mice. D and E, Number of tumors in control (Ctrl) and ALK vaccinated 
(Vax) mice as measured by MRI at the indicated time points. EML4-ALK mice (D, Ctrl = 24 
mice; Vax = 26 mice) from three independent experiments. TFG-ALK mice (E, Ctrl = 5 
mice; Vax = 9 mice) from two independent experiments. The average number of tumors 
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for each cohort (± SEM) is displayed. F and G, Overall survival by Kaplan-Meier curves in 
EML4-ALK mice (F) and TFG-ALK mice (G). **, P<0.005; ***, P<0.0005; ****, P<0.0001. 
 
Figure 3. ALK vaccine increases the number of intratumoral T lymphocytes and 
depends on cytotoxic CD8+ T cells. A, Representative hematoxilin-eosin (H&E) and 
immunostaining with anti-CD3 antibody of lung sections from control (Ctrl) and ALK 
vaccinated (Vax) EML4-ALK mice. Scale bars, 100µm. B, Histograms represent the 
percentage of CD3+ cells infiltrating the tumors in control (Ctrl) and ALK vaccinated mice 
(Vax) in EML4-ALK (left) and in TFG-ALK (right) mice at 12 weeks of age. C, Histograms 
represent the mean percentages of CD8+ and CD4+ T cells infiltrating the tumors and the 
CD8+/CD4+ ratio in control and vaccinated EML4-ALK mice at 12 weeks of age. D, 
Representative immunostaining with anti-Foxp3 antibody of lung sections from EML4-ALK 
control (Ctrl) and ALK vaccinated (Vax) mice (left). Scale bars, 100µm. E, Mean 
percentages of intratumoral Treg cells (Foxp3+ cells; left) and CD8+/Foxp3+ cell ratio (right) 
in control and vaccinated EML4-ALK mice. F, Schematic representation of the vaccination 
protocol in combination with CD4+ or CD8+cell depletion. G, Mean lung tumor numbers (n= 
5 mice for each group). Data are from two independent experiments. H, Representative 
lung sections of ALK vaccinated mice in combination with CD4+ cell depletion or CD8+cell 
depletion. Data are represented as mean (±SEM). *, P<0.05; ****, P<0.0001. 
 
Figure 4. ALK induces an immunosuppressive microenvironment in ALK-rearranged 
NSCLC. A, Lung immune infiltrates were stained with antibodies to CD3, CD4, CD8, PD-1 
and analyzed by flow cytometry. Histograms show the mean percentage for each indicated 
population in WT mice (□, n= 5 mice), 12-week-old EML4-ALK mice (□, n= 5 mice) and 
16-week-old EML4-ALK mice (■, n=9 mice). B, Immunohistochemistry for CD3, CD4 and 
CD8 on a representative mutated EGFR (ex19del) patient (left panels) and a 
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representative EML4-ALK positive NSCLC case (right panels). Scale bars, 100µm. Graphs 
show the percentages of CD3+, CD4+ and CD8+ cells in EML4-ALK positive NSCLC vs 
EGFR mutated patients. Horizontal bars represent means. C, Gene Set Enrichment 
Analysis (GSEA) for T cell markers based on gene expression profiling of human EML4-
ALK NSCLC vs EGFR mutated NSCLC (L858R or EGFR-Del19) (FDR q-Value: 0.008, top 
panel) or vs K-RAS mutated NSCLC (FDR q-Value: 0.001, central panel) or vs K-
RAS/EGFR/ALK negative NSCLC (FDR q-Value: 0.00046, bottom panel). *, P<0.05; **, 
P<0.005; ***, P<0.0005. 
 
Figure 5. Blockade of the PD-1/PD-L1 pathway restores the efficacy of the ALK 
vaccine against cells expressing high PD-L1. A, Western blot of H3122 cells treated 
with different crizotinib concentrations and collected at the indicated time points. 
Membranes were blotted with the indicated antibodies. B, PD-L1 protein expression was 
evaluated by flow cytometry in H3122 cells treated with 150nM crizotinib for 24 hours. C, 
PD-L1 mRNA expression was evaluated by qRT-PCR in crizotinib-treated cells. D, PD-L1 
expression was evaluated by flow cytometry in ASB-XIV cells (Ctrl), EML4-ALK ASB-XIV 
(EML-ALK) and in EML4-ALK ASB-XIV transduced with PD-L1 (EML4-ALK/PD-L1). E, 
Mean tumor numbers in lungs from mice injected with the indicated ASB-XIV cells (n= 5 
mice for each group). F, Mean tumor numbers in lungs from mice with the indicated 
treatments (n= 6-8 mice for each group). Data are represented as mean (±SEM). G and H, 
Quantification of volume changes compared to baseline tumors in ALK mice treated with 
control IgG (n=6 mice) or anti-PD-1 antibody (n=7 mice) at the end of treatment (G) and at 
4 weeks after treatment suspension (H). Horizontal bars represent means. Data are from 
two independent experiments. *, P<0.05; **, P<0.005; ***, P<0.0005. 
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Figure 6. ALK vaccine is efficacious in combination with crizotinib treatment. A, 
Schematic representation of the ALK vaccination combined with crizotinib treatment in 
EML4-ALK mice. B, Cytotoxic activity in ALK vaccinated mice in combination with 
crizotinib. Horizontal bars represent means. C, Representative MRI of crizotinib-treated 
mice and crizotinib-treated plus vaccinated mice. Arrows indicate tumor recurrence in the 
same position. Arrowheads indicate new tumors. D and E, The number of tumors (D) and 
the tumor volume (E) were measured by MRI analysis at the indicated time points. Data 
are from two independent experiments. Data are represented as mean (±SEM). **, 
P<0.005; ***, P<0.0005. 
 
Figure 7. ALK vaccine is effective in tumors with crizotinib resistant EML4-ALK 
mutants. A, Western Blot shows the expression of EML4-ALK wild-type or the EML4-ALK 
mutants (C1156Y, F1174L and L1196M) in ASB-XIV infected cells and in human ALK-
rearranged NSCLC cell line (H3122). The lines between the blots indicate cut lanes on the 
same gel. B-E, Representative H&E sections of the lungs of control (Ctrl) and ALK 
vaccinated (Vax) mice at day 21 after injection i.v. of ASB-XIV cells infected with a GFP 
plasmid expressing EML4-ALK WT (B) or the EML4-ALK mutants C1156Y (C), L1196M 
(D) or F1174L (E). Histograms represent the number of tumors in control (Ctrl; n=3 mice 
for each EML4-ALK construct) and ALK vaccinated mice (Vax; n=3 mice for each EML4-
ALK construct). Scale bars, 1mm. Data are from two independent experiments. Data are 
represented as mean (±SEM). *, P<0.05; **, P<0.005; ***, P<0.0005. 
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